The European and Developing Countries clinical trials partnership (EDCTP) have granted 10million Euros to WANECAM 2 to complete production of new malaria drugs.
The WANECAM 2 collaboration involve antimalarial drug researchers from 9 academic institutions Novartis pharmaceutical company and not-for-profit product development partnership (PDP), Medicines for malaria venture.
The collaboration is to support African trials of a novel antimalarial combination of KAF 156 (ganaplacide) and lumefantrine as new once-daily formulation.
However, this action is key in order to accelerate development in the much needed compound because a recent survey showed high levels of concern around resistance to some of the current gold-standard treatments, artemisinin combination therapies (ACTs).
(NAN)